Journal
TRENDS IN PARASITOLOGY
Volume 29, Issue 5, Pages 207-212Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.pt.2013.03.004
Keywords
Trypanosoma brucei; endocytosis; suramin; trypanolytic factor; drug delivery
Categories
Funding
- Wellcome Trust [082813, 093010/Z/10/Z]
- Medical Research Council [MR/K011987/1, MR/K008749/1, MR/K000500/1]
- MRC [MR/K008749/1, MR/K011987/1, MR/K000500/1] Funding Source: UKRI
- Medical Research Council [MR/K008749/1, MR/K000500/1, MR/K011987/1] Funding Source: researchfish
- Wellcome Trust [100320/Z/12/Z] Funding Source: researchfish
Ask authors/readers for more resources
Bloodstream-form cells of Trypanosoma brucei exhibit massively increased endocytic activity relative to the insect midgut stage, enabling rapid recycling of variant surface glycoprotein and antibody clearance from the surface. In addition, recent advances have identified a role for receptor-mediated endocytosis in the uptake of the antitrypanosomal drug, suramin, via invariant surface glycoprotein 75, and in the uptake of trypanosome lytic factor 1 via haptoglobin-haemoglobin receptor. Here, we argue that receptor-mediated endocytosis represents both a validated drug target and a promising route for the delivery of novel therapeutics into trypanosomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available